Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Prim. 2024;10:45. https://doi.org/10.1038/s41572-024-00529-7.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. https://doi.org/10.3322/caac.21708.

Article  PubMed  Google Scholar 

Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, et al. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023;29:4784–96. https://doi.org/10.1158/1078-0432.Ccr-23-0235.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Visram A, Chan KKW, Seow H, Pond G, Gayowsky A, McCurdy A, et al. Comparison of the efficacy in clinical trials versus effectiveness in the real world of treatments for multiple myeloma: A population-based cohort study. Blood. 2023;142:541. https://doi.org/10.1182/blood-2023-189506.

Article  Google Scholar 

Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, et al. Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:8–17.e16. https://doi.org/10.1016/j.clml.2019.09.625.

Article  PubMed  Google Scholar 

Duma N, Azam T, Riaz IB, Gonzalez-Velez M, Ailawadhi S, Go R. Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. Oncologist. 2018;23:1076–8. https://doi.org/10.1634/theoncologist.2017-0592.

Article  PubMed  PubMed Central  Google Scholar 

Mian H, McCurdy A, Giri S, Grant S, Rochwerg B, Winks E, et al. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. Blood Cancer J. 2023;13:6. https://doi.org/10.1038/s41408-022-00779-2.

Article  PubMed  PubMed Central  Google Scholar 

Cook G, Pawlyn C, Royle K-L, Senior E, Dax E, Bird J, et al. Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study. Blood. 2023;142:4748. https://doi.org/10.1182/blood-2023-188672.

Article  Google Scholar 

Mian H, Wildes TM, Vij R, Pianko MJ, Major A, Fiala MA. Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. Blood Cancer J. 2023;13:76. https://doi.org/10.1038/s41408-023-00843-5.

Article  PubMed  PubMed Central  Google Scholar 

Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017;3:28–35. https://doi.org/10.1001/jamaoncol.2016.3160.

Article  PubMed  PubMed Central  Google Scholar 

Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, et al. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39:1139–49. https://doi.org/10.1200/jco.20.01814.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Avet-Loiseau H, Corre J, Lauwers-Cances V, Chretien M-L, Robillard N, Leleu X, et al. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. Blood. 2015;126:191. https://doi.org/10.1182/blood.V126.23.191.191.

Article  Google Scholar 

Oliva S, D’Agostino M, Boccadoro M, Larocca A. Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma. Front Oncol. 2020;10:1. https://doi.org/10.3389/fonc.2020.00001.

Article  PubMed  PubMed Central  Google Scholar 

Abu Za’nouneh FJ, Ababneh O, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD Jr, et al. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023;4:454–8. https://doi.org/10.1002/jha2.675.

Article  PubMed  PubMed Central  Google Scholar 

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9. https://doi.org/10.1200/JCO.2015.61.2267.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40:3406–18. https://doi.org/10.1200/jco.21.02614.

Article  PubMed  Google Scholar 

Marcon C, Simeon V, Deias P, Facchin G, Corso A, Derudas D, et al. Experts’ consensus on the definition and management of high risk multiple myeloma. Front Oncol. 2022;12:1096852. https://doi.org/10.3389/fonc.2022.1096852.

Article  PubMed  Google Scholar 

Hagen P, Zhang J, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022;12:83. https://doi.org/10.1038/s41408-022-00679-5.

Article  PubMed  PubMed Central  Google Scholar 

Hartley-Brown M, Cole CE, Price P, Andreini M, Mulligan G, Young AQ, et al. Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:32–39. https://doi.org/10.1016/j.clml.2023.09.004.

Article  PubMed  Google Scholar 

El-Cheikh J, Moukalled N, Malard F, Bazarbachi A, Mohty M. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J. 2023;13:83. https://doi.org/10.1038/s41408-023-00849-z.

Article  PubMed  PubMed Central  Google Scholar 

Jeremias, S. Dr Joseph Mikhael on Strategies to Increase Diversity in Multiple Myeloma Trials. Comm. 2023.

Gormley N, Fashoyin-Aje L, Locke T, Unger JM, Little RF, Nooka A, et al. Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. Blood Cancer Discov. 2021;2:119–24. https://doi.org/10.1158/2643-3230.BCD-20-0123.

Article  PubMed  PubMed Central  Google Scholar 

Wu C, Dongarwar D, Al Hadidi S. Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States. Clin Hematol Int. 2023;5:1–9. https://doi.org/10.46989/001c.87755.

Article  CAS  PubMed  Google Scholar 

Ibrahim A, Chamseddine N, El-Cheikh J, Hanna C, Moukadem W, Nasr F, et al. Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective. Clin Hematol Int. 2022;4:127–32. https://doi.org/10.1007/s44228-022-00017-3.

Article  PubMed  PubMed Central  Google Scholar 

Tso ACY, Wang SSY, Gallardo CA, Christopher D, Ong KH. Tolerability of Daratumumab Amongst Asian Patients with Plasma Cell Dyscrasias - A Single Centre Experience. Clin Hematol Int. 2024;6:16–22. https://doi.org/10.46989/001c.92085.

Article  PubMed  PubMed Central  Google Scholar 

Kaedbey R, Reece D, Venner CP, McCurdy A, Su J, Chu M, et al. Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database. EJHaem. 2024;5:474–84. https://doi.org/10.1002/jha2.894.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024. https://doi.org/10.1016/s1470-2045(24)00282-1.

Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016;128:2757–64. https://doi.org/10.1182/blood-2016-09-692947.

Article  CAS  PubMed  PubMed Central  Google Scholar